IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Pediatric Oral Sedation: An Evidence-Based Review of Pharmacological Agents and Safe Clinical Practice

[1]Dr. Harshini Sadhu, [2]Dr. B. N. Rangeeth, [3]Dr. O. K. Sruthi, [4]Dr. Shruthi Naarayani R,

[5]Dr. Qurathul Ayn Fathima M. J

[1]Post-Graduate Student, [2]Head of the Department, [3]Assistant Professor, [4]Post-Graduate Student, [5]Post-Graduate Student

[1]Department of Pediatric Dentistry,

[1]Thai Moogambigai Dental College and Hospital, Chennai, India

Abstract: Oral sedation plays a pivotal role in pediatric dentistry by facilitating the management of dental anxiety, fear, and uncooperative behavior, thereby enabling the successful completion of dental procedures. A variety of pharmacological agents have been employed for this purpose, including benzodiazepines, nonbenzodiazepine GABA agonists, antihistamines, melatonin, ketamine, chloral hydrate, and α2-adrenergic agonists such as dexmedetomidine. Among these, midazolam remains the most widely utilized oral sedative due to its favorable safety profile, rapid onset, predictable pharmacokinetics, and effective anxiolytic and amnestic properties. Emerging agents such as dexmedetomidine have demonstrated promising results, offering effective sedation with minimal respiratory depression and improved postoperative recovery. This review provides a comprehensive overview of the administration protocols, safety considerations, mechanisms of action, pharmacokinetics, dosage recommendations, clinical efficacy, adverse effects, and reversal agents associated with oral sedatives used in pediatric dentistry. Understanding the advantages and limitations of each agent is essential for optimizing patient safety, enhancing treatment outcomes, and ensuring evidence-based sedation practices in contemporary pediatric dental care.

Index Terms - Pediatric Dentistry; Oral Sedation; Midazolam; Dexmedetomidine; Behavior Management.

I. INTRODUCTION

The success of oral sedation largely depends on the pharmacological properties of the sedative agents employed. Over the past several decades, a diverse range of drugs has been utilized for oral sedation, including benzodiazepines, antihistamines, chloral hydrate, barbiturates, opioids, and, more recently, α2-adrenergic agonists. Each class of medication possesses unique pharmacodynamic and pharmacokinetic characteristics that influence onset of action, duration of sedation, anxiolytic efficacy, amnesic properties, recovery profile, and adverse effect potential.[1] Benzodiazepines, particularly midazolam and diazepam, have emerged as the cornerstone of oral sedation because of their favorable safety profile, predictable anxiolytic effects, and wide therapeutic index. Simultaneously, newer agents such as dexmedetomidine have garnered increasing attention due to their sedative and analgesic properties with minimal respiratory depression.[2]

Prior to drug administration, a thorough medical history, physical examination, and assessment of the patient's anxiety level, behavioral status, and systemic health are essential to determine suitability for sedation. Sedative medications are typically administered 20–60 minutes before the planned procedure, depending on the agent used, with dosing tailored according to patient age, weight, medical condition, and treatment

requirements. Continuous monitoring of vital signs, including oxygen saturation, heart rate, respiratory rate, and level of consciousness, remains imperative throughout the procedure and recovery period to ensure patient safety and early detection of adverse events.[3,4]

Recent advances in sedation pharmacology and monitoring technologies have significantly enhanced the safety and predictability of oral sedation.[5] Nevertheless, growing concerns regarding adverse drug reactions, variability in clinical outcomes, and the increasing use of newer sedative agents necessitate a comprehensive understanding of administration techniques and associated complications.[6] A thorough evaluation of current evidence regarding the principles of oral sedation administration and its potential side effects is therefore essential for optimizing patient safety, improving treatment outcomes, and guiding evidence-based clinical decision-making.[7,8]

II. PRE-SEDATION ASSESSMENT AND PATIENT PREPARATION FOR ORAL SEDATION

This evaluation includes a thorough review of the patient's medical history, encompassing systemic illnesses, previous anesthetic or sedation experiences, known drug allergies, and current medications that may interact with sedative agents. A focused physical examination should be conducted with particular attention to cardiovascular and respiratory health, while also assessing factors that may compromise the airway, such as obesity, enlarged tonsils, craniofacial abnormalities, increased neck circumference, or a history of obstructive sleep apnea. Equally important is the assessment of the patient's psychological status, including the degree of anxiety, fear, and behavioral cooperation, as these factors influence the choice and dosage of sedative medications. Risk stratification using established guidelines, such as the American Society of Anesthesiologists (ASA) classification system, helps determine the suitability of patients for oral sedation, with ASA I and II patients generally considered appropriate candidates, whereas patients with higher ASA classifications may require specialized evaluation or alternative sedation approachesStandard recommendations typically require abstinence from solid foods for at least six hours before the procedure, while clear fluids may be permitted up to two hours beforehand. Special considerations should be made for children with medical conditions such as diabetes or metabolic disorders, where individualized fasting and medication protocols may be necessary. [10,11]

III. SEDATIVE SELECTION, PREPARATION, AND ADMINISTRATION PROTOCOL FOR ORAL SEDATION

The choice of sedative should be individualized based on the duration and complexity of the dental procedure, the child's medical status, behavioral characteristics, anxiety level, and the desired depth of sedation. Once the appropriate agent has been selected, the dosage must be calculated carefully according to the patient's body weight, age, and overall health status, typically using weight-based dosing (mg/kg). Lower doses may be necessary in medically compromised patients due to altered drug metabolism and elimination. To minimize the risk of adverse effects and over-sedation, clinicians should initiate treatment with the lowest effective dose and allow sufficient time for the drug to achieve its peak effect before considering supplemental dosing. Preparation of the sedative depends on the available formulation and patient preference. Tablets or capsules should be verified for appropriate dosage and suitability for oral administration, while liquid formulations should be measured precisely using calibrated syringes or dosing devices and may be mixed with a small amount of a palatable liquid to improve acceptance.[11,12]

Orally disintegrating tablets provide an alternative for children who have difficulty swallowing conventional tablets and may offer a more rapid onset of action. Administration techniques should ensure patient comfort and safety, with tablets swallowed using a small amount of water, orally disintegrating tablets allowed to dissolve on the tongue, and liquid medications delivered slowly through an oral syringe to avoid choking or medication loss. Sedatives are generally administered 30–60 minutes before the dental procedure, depending on the pharmacokinetic profile of the selected drug, to ensure optimal therapeutic effect at the start of treatment. Objective sedation assessment tools, such as the Ramsay Sedation Scale, may be employed to evaluate the depth of sedation and guide clinical decision-making. If sedation is deemed inadequate after the expected onset period, carefully calculated supplemental doses may be considered within established safety limits, always prioritizing patient safety and avoiding excessive sedation.[13,14,15,16,17]



Drugs Commonly Used for Oral Sedation in Pediatric Dentistry



IV. BENZODIAZEPINES IN PEDIATRIC DENTISTRY

Benzodiazepines represent one of the most widely utilized classes of sedative agents in pediatric dentistry owing to their excellent anxiolytic, sedative, amnestic, and muscle-relaxant properties coupled with a favorable safety profile. Their pharmacological action is mediated through potentiation of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter of the central nervous system. Benzodiazepines bind to specific benzodiazepine receptor sites located on the GABA $_A$ receptor complex, enhancing the affinity of GABA for its receptor and increasing the frequency of chloride ion channel opening. This results in neuronal hyperpolarization and reduced excitability, producing sedation and anxiolysis without directly activating the receptor, thereby contributing to their wide therapeutic margin and safety. Among this class, diazepam has historically been one of the most extensively used agents because of its rapid onset of action resulting from high lipid solubility. However, its long elimination half-life and active metabolites can lead to prolonged sedation, residual drowsiness, and a “hangover” effect, limiting its contemporary use. Clinical evidence supports the efficacy of diazepam in managing pediatric dental anxiety; a study by Yanase et al. demonstrated that oral diazepam administered at a dose of 0.3 mg/kg before treatment significantly improved cooperative behavior in fearful and uncooperative children without producing adverse effects such as respiratory depression or vomiting. Comparative investigations by Tyagi et al. further evaluated oral diazepam, oral midazolam, and intravenous midazolam in children undergoing dental treatment and reported that while oral diazepam effectively improved behavior and reduced anxiety, oral midazolam produced superior outcomes, with intravenous midazolam demonstrating the greatest sedative and anxiolytic effects.

V. LORAZEPAM, TRIAZOLAM, AND MIDAZOLAM IN PEDIATRIC DENTISTRY

Lorazepam is an intermediate-acting benzodiazepine with a half-life of approximately 10–20 hours and produces reliable anxiolytic and sedative effects due to its high oral bioavailability and metabolism through glucuronidation, which generates inactive metabolites and minimizes the influence of age, hepatic dysfunction, and drug interactions. Clinical evidence from Mundeleer et al. demonstrated that lorazepam effectively reduces preoperative anxiety in children at doses of 0.04–0.05 mg/kg, with higher doses increasing sedation without providing additional amnestic benefits. Triazolam, a short-acting benzodiazepine originally developed for insomnia, has gained popularity in dentistry because of its rapid onset, short duration of action, and absence of active metabolites, thereby reducing the risk of prolonged sedation. [21,22]

However, studies by Coldwell et al. revealed a dose-dependent increase in adverse effects such as ataxia, amnesia, diplopia, and visual disturbances, particularly at higher doses. Among all benzodiazepines, midazolam has emerged as the preferred oral sedative in pediatric dentistry owing to its rapid onset, short elimination half-life, predictable pharmacokinetic profile, and favorable safety record. Administered orally at doses ranging from 0.25 to 1.0 mg/kg, midazolam produces sedation, anxiolysis, anterograde amnesia, muscle relaxation, and anticonvulsant effects within 15–30 minutes, with clinical effects typically lasting 30–45 minutes. Its availability as a palatable syrup further enhances patient acceptance and ease of administration in children. Although generally safe, adverse effects such as respiratory depression, paradoxical agitation, apnea, and hypotension may occur, particularly at higher doses, necessitating appropriate monitoring. Clinical investigations have consistently demonstrated its effectiveness; Kain et al. reported reduced anxiety during anesthesia induction and fewer negative postoperative behavioral changes among children receiving midazolam premedication, while a systematic review by Manso et al. found significantly higher sedation success rates with oral midazolam compared with placebo, with efficacy increasing at doses above 0.25 mg/kg[23-25].

VI. NONBENZODIAZEPINE GABA AGONISTS (Z-DRUGS)

Nonbenzodiazepine GABA agonists, commonly referred to as Z-drugs, were developed to provide effective sedation and anxiolysis while minimizing some of the undesirable effects associated with traditional benzodiazepines. Although structurally distinct from benzodiazepines, these agents act on the benzodiazepine receptor site of the $GABA_A$ receptor complex, exhibiting greater selectivity for the α1 receptor subunit, which is primarily responsible for hypnotic and sedative effects. This receptor selectivity contributes to effective sedation with a lower incidence of residual drowsiness, cognitive impairment, muscle relaxation, and abuse potential compared with conventional benzodiazepines. Among the available agents, zolpidem is the most extensively studied and is characterized by a rapid onset of action, short elimination half-life, and minimal next-day residual effects.[26] Clinical research by Derakhshan et al. demonstrated that both zolpidem and midazolam significantly reduced preoperative anxiety in children; however, zolpidem was found to be more effective in alleviating anxiety and improving cooperation, suggesting its potential as an alternative premedication agent in pediatric patients. Eszopiclone, the active S-enantiomer of zopiclone, possesses similar pharmacokinetic characteristics and can also be antagonized by flumazenil, although evidence regarding its use in dental sedation remains limited. Zaleplon is another ultra-short-acting nonbenzodiazepine hypnotic with a very rapid onset and brief duration of action, making it suitable for short procedures requiring anxiolysis without prolonged recovery. A study by Ganzberg et al. reported that 10 mg of zaleplon produced anxiolytic and sedative effects comparable to 0.5 mg of triazolam, while allowing significantly faster recovery and causing minimal amnesia.[27]

VII. ANTIHISTAMINES IN PEDIATRIC DENTAL SEDATION: PHARMACOLOGY, CLINICAL APPLICATIONS, AND EFFICACY

Hydroxyzine is considered one of the safest antihistamines for sedation because it has minimal effects on cardiovascular and respiratory function, a rapid onset of action, and a relatively low incidence of adverse effects.[27] Clinical studies have shown that combining hydroxyzine with midazolam can reduce crying and movement during dental treatment, thereby enhancing sedation quality in young children. Diphenhydramine, another commonly used H1-antagonist, possesses sedative, antiemetic, and anticholinergic properties and has demonstrated effectiveness when combined with midazolam, resulting in faster onset of sedation and improved sedation scores without prolonging recovery time. However, its anticholinergic effects, including dry mouth and airway drying, may occasionally be undesirable. Promethazine, a phenothiazine derivative with potent sedative and antiemetic actions, has also been used in pediatric sedation protocols, although concerns regarding respiratory depression have led to an FDA Black Box warning contraindicating its use in children younger than two years of age.[29] Clinical investigations suggest that while promethazine-containing combinations may provide sedation, they are generally less effective than regimens incorporating ketamine and midazolam. In pediatric dental practice, antihistamines are particularly valuable for reducing preoperative anxiety, preventing allergic reactions, controlling nausea and vomiting, and enhancing the effects of other sedative agents. Nevertheless, when compared with benzodiazepines such as midazolam, antihistamines produce less profound sedation and do not reliably induce amnesia. Consequently, benzodiazepines remain the preferred agents for moderate sedation and anxiety control, whereas antihistamines are most appropriately used as adjunctive medications or in situations where their additional antiemetic and antiallergic benefits are clinically advantageous.[30]

VIII. MELATONIN IN PEDIATRIC SEDATION: MECHANISM, CLINICAL APPLICATIONS, AND THERAPEUTIC POTENTIAL

Melatonin (5-methoxy-N-acetyltryptamine) is an endogenous hormone secreted by the pineal gland that plays a central role in regulating circadian rhythms and the sleep–wake cycle. Owing to its natural origin, favorable safety profile, and diverse pharmacological properties, including hypnotic, sedative, anxiolytic, antioxidant, immunomodulatory, and anti-inflammatory effects, melatonin has gained attention as a potential sedative agent in pediatric medicine and dentistry. Its mechanism of action involves binding to melatonin receptors in the central nervous system, thereby modulating circadian rhythms and facilitating the initiation and maintenance of sleep.[31] Age-specific dosing recommendations generally range from 1–2 mg for preschool children, 2–3 mg for school-aged children, and approximately 5 mg for adolescents. Compared with conventional sedatives, melatonin offers several advantages, including minimal adverse effects, lack of respiratory depression, absence of dependency or withdrawal potential, and greater acceptance among parents seeking natural therapeutic alternatives.[32] Nevertheless, mild side effects such as dizziness, fatigue, excessive drowsiness, agitation, mood changes, and occasional nocturnal enuresis have been reported, particularly at higher doses. In clinical practice, melatonin has been explored for preoperative anxiolysis, procedural sedation, management of sleep disorders, and reduction of anxiety associated with medical and dental interventions.[33] However, evidence regarding its sedative efficacy remains inconsistent. A systematic review by Gitto et al., involving 407 pediatric patients, evaluated melatonin as a preanesthetic sedative and found that most studies reported sedation outcomes comparable to placebo and generally inferior to standard sedatives.[34]

IX. KETAMINE IN PEDIATRIC DENTISTRY: AN NMDA RECEPTOR ANTAGONIST FOR SEDATION AND ANALGESIATYPE STYLE AND FONTS

Ketamine is a unique dissociative anesthetic that acts primarily as an N-methyl-D-aspartate (NMDA) receptor antagonist and has become an important pharmacological agent in pediatric sedation due to its combined sedative, analgesic, and amnestic properties. Orally administered ketamine exhibits a bioavailability of approximately 20%, with an onset of action around 20 minutes and a duration of effect ranging from 20 to 120 minutes. It undergoes extensive hepatic metabolism through N-demethylation and hydroxylation, producing active metabolites that are subsequently excreted in urine.[36] Recommended oral doses for pediatric sedation generally range from 3 to 6 mg/kg. The principal advantages of ketamine include effective analgesia, reliable amnesia, minimal respiratory depression, and maintenance of cardiovascular function, making it

especially useful in children with respiratory concerns or those requiring deeper levels of sedation. Nevertheless, its use is associated with several adverse effects, including increased salivation, nausea, vomiting, hypertension, tachycardia, increased muscle tone, and emergence phenomena such as vivid dreams, hallucinations, or unpleasant recovery reactions. Consequently, careful patient selection and monitoring are essential during its administration. Evidence supporting ketamine's efficacy in pediatric dentistry is substantial. A systematic review by Samuel Oh et al., encompassing 25 clinical trials, found that 22 studies reported positive outcomes, demonstrating significant reductions in dental anxiety and improvements in behavioral cooperation among children receiving ketamine sedation. Similarly, Johnson et al. reported that oral ketamine administered at doses of 3–5 mg/kg provided effective dissociative sedation and analgesia for pediatric dental procedures.[37]

X. CHLORAL HYDRATE AND DEXMEDETOMIDINE IN PEDIATRIC DENTAL SEDATION

Chloral hydrate, a traditional sedative-hypnotic, has long been utilized for pediatric procedural sedation because of its psycho-sedative effects and ease of oral administration. Following administration, it is metabolized to trichloroethanol, the active metabolite responsible for central nervous system depression and sedation. Commonly administered at doses of 25–50 mg/kg (maximum 1 g), chloral hydrate produces sedation within approximately 30 minutes, with effects lasting around one hour. Although it has been widely used for minor dental and diagnostic procedures, its clinical utility is limited by potential adverse effects, including respiratory depression, hypotension, gastric irritation, nausea, vomiting, myocardial depression, and cardiac arrhythmias.[38] Furthermore, its prolonged half-life in neonates and infants raises concerns regarding delayed recovery. Clinical studies have demonstrated acceptable efficacy and safety in children; however, comparisons with newer agents have consistently shown advantages for midazolam-based regimens. Abdulhamid et al. reported successful sedation in most asthmatic children receiving chloral hydrate, although occasional respiratory depression was observed.[39] Similarly, Dallman et al. found that intranasal midazolam provided sedation comparable to chloral hydrate-promethazine combinations but with significantly faster recovery times, while Myers et al. demonstrated improved sedation quality when submucosal midazolam was used as an adjunct to chloral hydrate.[40]

In contrast, dexmedetomidine, a highly selective α_2-adrenergic receptor agonist, has emerged as a promising contemporary sedative for pediatric dental practice. Its mechanism involves inhibition of norepinephrine release within the central nervous system, producing sedation, anxiolysis, and analgesia while preserving respiratory function. Administered orally or intranasally at doses ranging from 1–4 μg/kg, dexmedetomidine produces sedation within 30–60 minutes and maintains hemodynamic stability, making it particularly attractive for pediatric patients.[41] Unlike many traditional sedatives, it causes minimal respiratory depression while providing effective anxiety control and postoperative analgesia.[42] Recent clinical investigations have highlighted its growing importance in pediatric dentistry. Mohite et al. reported that dexmedetomidine, particularly through the intranasal route, is both safe and effective for pediatric dental sedation and may represent a preferred alternative to conventional oral sedatives.[43] Similarly, Walye et al. demonstrated that oral dexmedetomidine and midazolam were both effective and safe; however, dexmedetomidine offered superior postoperative analgesia and faster recovery.[44]

XI. REVERSAL AGENTS FOR ORAL SEDATION IN PEDIATRIC DENTISTRYEASE OF USE

Flumazenil is a selective benzodiazepine antagonist that reverses the sedative, anxiolytic, and amnestic effects of benzodiazepines such as midazolam, diazepam, lorazepam, and triazolam. It acts by competitively binding to benzodiazepine receptor sites on the GABA$_A$ receptor complex, displacing benzodiazepines and rapidly reversing their central nervous system depressant effects.[44] In pediatric patients, flumazenil is typically administered intravenously at an initial dose of 0.01 mg/kg, with careful titration as needed.[46] Owing to its rapid onset and relatively short half-life of approximately 40–80 minutes, continuous monitoring is essential because re-sedation may occur once its effects diminish.[47] Although generally well tolerated, flumazenil may precipitate agitation, nausea, confusion, withdrawal symptoms, or seizures, particularly in patients with chronic benzodiazepine exposure or mixed-drug overdoses. Naloxone, on the other hand, is a pure opioid antagonist used to reverse opioid-induced sedation and respiratory depression. It exerts its effect by competitively binding to opioid receptors in the central nervous system, thereby displacing opioid agonists and restoring normal respiratory and neurological function.[48] In children, naloxone is typically administered at a dose of 0.01 mg/kg through intravenous, intramuscular, or intranasal routes and may be repeated

according to clinical response. The drug has a rapid onset of action and a half-life ranging from 30 to 90 minutes; however, because many opioids have longer durations of action than naloxone, repeated dosing or prolonged observation may be necessary to prevent recurrence of respiratory depression.[49] Adverse effects may include agitation, nausea, vomiting, tachycardia, and acute withdrawal symptoms in opioid-dependent individuals.[50]

XII. Conclusion

Oral sedation remains an invaluable adjunct in pediatric dentistry, facilitating the safe and effective management of anxiety, fear, and uncooperative behavior during dental procedures. A wide range of sedative agents, including benzodiazepines, antihistamines, ketamine, chloral hydrate, melatonin, and dexmedetomidine, offer distinct advantages and limitations based on their pharmacological profiles and clinical indications. Among these, midazolam and dexmedetomidine have emerged as preferred agents due to their favorable efficacy and safety characteristics. Regardless of the sedative selected, careful patient assessment, appropriate dosing, vigilant monitoring, and readiness to employ reversal agents are essential to ensure optimal sedation outcomes and patient safety in pediatric dental practice.

References

1. Wilson S editor. Oral Sedation for Dental Procedures in Children. Springer; 2015 Jul 21
2. American Society of Anesthesiologists. New classification of physical status. Anesthesiol. 1963;24:111.
3. Wilson S. Pharmacological management of the pediatric dental patient. Pediatr Dent. 2004 Mar 1;26(2):131–6.
4. Möhler H. Benzodiazepines. e LS. 2001 May 30.
5. Yanase H, Braham RL, Fukuta O, Kurosu K. A study of the sedative effect of home-administered oral diazepam for the dental treatment of children. Int J Paediatr Dent. 1996 Mar;6(1):13-7. doi: 10.1111/j.1365-263x.1996.tb00202.x. PMID: 8695584.
6. Tyagi P, Tyagi S, Jain A. Sedative effects of oral midazolam, intravenous midazolam and oral diazepam in the dental treatment of children. J Clin Pediatr Dent. 2013 Spring;37(3):301-5. doi: 10.17796/jcpd.37.3.6u482603r0388558. PMID: 23855176.
7. Mundeleer P. Child premedication per os with lorazepam. Acta Anaesthesiol Belg. 1980;31 Suppl:187-93. PMID: 6109421.
8. Coldwell SE, Awamura K, Milgrom P, Depner KS, Kaufman E, Preston KL, Karl HW. Side effects of triazolam in children. Pediatr Dent. 1999 Jan-Feb;21(1):18-25. PMID: 10029963.
9. Kain ZN, Mayes LC, Wang SM, Hofstadter MB. Postoperative behavioral outcomes in children: effects of sedative premedication. Anesthesiology. 1999 Mar;90(3):758-65. doi: 10.1097/00000542-199903000-00018. PMID: 10078677.
10. Manso MA, Guittet C, Vandenhende F, Granier L-A. Efficacy of oral midazolam for minimal and moderate sedation in pediatric patients: A systematic review. Pediatr Anesth. 2019; 29: 1094–1106. https://doi.org/10.1111/pan.13747
11. Cengiz M, Baysal Z, Ganidagli S. Oral sedation with midazolam and diphenhydramine compared with midazolam alone in children undergoing magnetic resonance imaging. Paediatr Anaesth. 2006 Jun;16(6):621-6. doi: 10.1111/j.1460-9592.2005.01820.x. PMID: 16719877.
12. Lu J, Greco MA. Sleep circuitry and the hypnotic mechanism of GABAA drugs. J Clin Sleep Med. 2006;2(2):S19–26.

13. Derakhshan, Pooya & Faiz, Hamid Reza & Emami, Azadeh & Mohseni, Masood & Shirani, Mohsen. (2020). A Double-Blind Clinical Trial to Determine the Effect of Oral Zolpidem and Midazolam on the Level of Preoperative Anxiety in Children Undergoing Eye Examination Under General Anesthesia. Iranian Journal of Pediatrics. In Press. 10.5812/ijp.102183.

14. Kurta DL, Myers LB, Krenzelok EP. Zolpidem (Ambien): a pediatric case series. J Toxicol Clin Toxicol. 1997;35(5):453-7. doi: 10.3109/15563659709001227. PMID: +9279301

15. Ganzberg SI, Dietrich T, Valerin M, Beck FM. Zaleplon (Sonata) oral sedation for outpatient third molar extraction surgery. Anesth Prog. 2005 Winter;52(4):128-31. doi: 10.2344/0003-3006(2005)52[128:ZOS]2.0.CO;2. PMID: 16596911; PMCID: PMC1586798.

16. Rickels K, Morris RJ, Newman H, Rosenfeld H, Schiller H, Weinstock R. Diphenhydramine in insomniac family practice patients: a double-blind study. J Clin Pharmacol. 1983;23:234–42.

17. Shapira J, Kupietzky A, Kadari A, Fuks AB, Holan G. Comparison of oral midazolam with and without hydroxyzine in the sedation of pediatric dental patients. Pediatr Dent. 2004 Nov-Dec;26(6):492-6. PMID: 15646910.

18. Ritwik P, Cao LT, Curran R, Musselman RJ. Post-sedation events in children sedated for dental care. Anesth Prog. 2013 Summer;60(2):54-9. doi: 10.2344/0003-3006-60.2.54. PMID: 23763560; PMCID: PMC3683881.

19. Golpayegani MV, Dehghan F, Ansari G, Shayeghi S. Comparison of oral Midazolam-Ketamine and Midazolam-Promethazine as sedative agents in pediatric dentistry. Dent Res J (Isfahan). 2012 Jan;9(1):36-40. doi: 10.4103/1735-3327.92925. PMID: 22363361; PMCID: PMC3283976.

20. Kim T, Kim K, Kim S, Kim J. Safety of hydroxyzine in the sedation of pediatric dental patients. J Dent Anesth Pain Med. 2022 Dec;22(6):395-404. doi: 10.17245/jdapm.2022.22.6.395. Epub 2022 Nov 24. PMID: 36601135; PMCID: PMC9763820

21. Gitto E, Marseglia L, D'Angelo G, Manti S, Crisafi C, Montalto AS, Impellizzeri P, Reiter RJ, Romeo C. Melatonin versus midazolam premedication in children undergoing surgery: A pilot study. J Paediatr Child Health. 2016 Mar;52(3):291-5. doi: 10.1111/jpc.13007. Epub 2015 Oct 29. PMID: 26515269.

22. Karapinar V, Yilmaz D, Demirag K, Kantar M. Sedation with intravenous ketamine and midazolam for painful procedures in children. Pediatr Int. 2006;48:146–51.

23. Sasada MP, Smith SP. Drugs in Anesthesia and Intensive Care. Oxford: Oxford University Press; 1997.

24. Oh S, Kingsley K. Efficacy of Ketamine in Pediatric Sedation Dentistry: A Systematic Review. Compend Contin Educ Dent. 2018 May;39(5):e1-e4. PMID: 29714490.

25. Jency Samuel Johnson,Savitha Sathyaprasad(2014). Ketamine: Angel Dust in Pediatric Dental Sedation.. Research & Reviews: Journal of Dental Sciences,

26. National Center for Biotechnology Information. PubChem Compound Summary for CID 2707. Chloral Hydrate; 2023.

27. Morgenstern J. ChloralHydrate Toxicity. First10EM; April 3, 2017

28. Abdulhamid I, Tremblay M, Stenger J, Tutag Lehr V. Chloral hydrate for sedation of children with asthma during dental treatment. Eur J Paediatr Dent. 2016 Jun;17(2):141-6. PMID: 27377113.

29. Dallman JA, Ignelzi MA Jr, Briskie DM. Comparing the safety, efficacy and recovery of intranasal midazolam vs. oral chloral hydrate and promethazine. Pediatr Dent. 2001 Sep-Oct;23(5):424-30. PMID: 11699169.

30. Myers GR, Maestrello CL, Mourino AP, Best AM. Effect of submucosal midazolam on behavior and physiologic response when combined with oral chloral hydrate and nitrous oxide sedation. Pediatr Dent. 2004 Jan-Feb;26(1):37-43. PMID: 15080356.

31. Vedangi Mohite,Sudhindra Baliga, Nilima Thosar, Nilesh Rathi. (2019). Role of dexmedetomidine in pediatric dental sedation.. Journal of Dental Anesthesia and Pain Medicine, doi: 10.17245/JDAPM.2019.19.2.83
32. Salwa H Waly(2019). Dexmedetomidine versus midazolam for conscious sedation in children undergoing dental procedures. doi: 10.4103/ROAIC.ROAIC_90_18
33. Donaldson M, Gizzarelli G, Chanpong B. Oral sedation: a primer on anxiolysis for the adult patient. Anesth Prog. 2007;54(3):118–29.
34. Verywell Health. (2023, September 27). Oral sedation dentistry: What to expect. https://my.clevelandclinic.org/health/treatments/22275-sedation-dentistry
35. Eslaamizaad S, Toopch S. Sedation in pediatric dentistry. Acta Scienti Dent Sci. 2019;3(2):40–6.
36. Joginder, Pal, Attri., Radhe, Sharan., Vega, Makkar., Kewal, Krishan, Gupta., Ranjana, Khetarpal., Amar, Parkash, Kataria. (2017). Conscious Sedation: Emerging Trends in Pediatric Dentistry.. Anesthesia: Essays and Researches, doi: 10.4103/0259-1162.171458
37. Jagdish, P., & Bhaskar, D. J. (2014). Advantages of conscious sedation in dentistry: A review. Journal of Clinical and Diagnostic Research, 8(7), 2280-2283.
38. Nelson TM, Xu Z. Pediatric dental sedation: challenges and opportunities. Clin Cosmet Investig Dent. 2015 Aug 26;7:97–106.
39. Rodriguez E, Jordan R. Contemporary trends in pediatric sedation and analgesia. Emerg Med Clin. 2002 Feb 1;20(1):199–222.
40. Arathi Papineni, Liege Lourenço-Matharu, Paul Ashley. (2014). Safety of oral midazolam sedation use in paediatric dentistry: a review.. International Journal of Paediatric Dentistry, doi: 10.1111/IPD.12017
41. Jency Samuel Johnson,Savitha Sathyaprasad(2014). Ketamine: Angel Dust in Pediatric Dental Sedation.. Research & Reviews: Journal of Dental Sciences,
42. Annie Huang, Thomas Tanbonliong(2015). Oral Sedation Postdischarge Adverse Events in Pediatric Dental Patients..Anesthesia Progress, doi: 10.2344/0003-3006-62.3.91
43. Christopher Heard, Carrie Wanamaker(2015). Dental Sedation in Children. Current Anesthesiology Reports, doi: 10.1007/S40140-015-0110-0
44. Travis Nelson,Zheng Xu(2015). Pediatric dental sedation: challenges and opportunities. Clinical, Cosmetic and Investigational Dentistry, doi: 10.2147/CCIDE.S64250
45. Kwangwoo Baek(2015). Considerations for submucosal midazolam administration in combination with oral and inhaled medications for sedation of pediatric dental patients.. Journal of Dental Anesthesia and Pain Medicine, doi: 10.17245/JDAPM.2015.15.2.47
46. Alessandra Rodrigues de Almeida, Marcelo Medeiros, Luciane Rezende Costa (2015). Mothers' perceptions about pediatric dental sedation as an alternative to dental general anesthesia
47. B J S Diedericks. (2015). Paediatric dental sedation : will your child return home unharmed?. South African Medical Journal, doi: 10.7196/SAMJ.9756
48. Palak Jain,Prachi Pathak, Mousumi Goswami. (2021). Sedation with Midazolam in pediatric dentistry: A Review. Indian journal of applied research, doi: 10.36106/IJAR/1000302
49. Jacob Stern,Alexander Pozun(2021). Pediatric Procedural Sedation. Bernadette Aubert(2021). Pediatric Sedation. doi: 10.1093/med/9780197584521.003.0278

50. Mariana Garza, Rosa Isela Sanchez Najera, Enrique Nieto Ramirez,María Teresa Pérez Quintero,Sonia Lilia Aguilar Dominguez, Edith López Ramírez, M Paz,Juan Manuel Solis Soto(2022). Sedation in pediatric dentistry, an overview and current update. International Journal of Applied Dental Sciences, doi: 10.22271/oral.2022.v8.i2c.1507